- Home
- NTRB vs IVVD Comparison
NTRB vs IVVD Comparison
Compare NTRB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- IVVD
- Stock Information
- Founded
- NTRB 2016
- IVVD 2020
- Country
- NTRB United States
- IVVD United States
- Employees
- NTRB N/A
- IVVD N/A
- Industry
- NTRB Industrial Specialties
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- IVVD Health Care
- Exchange
- NTRB Nasdaq
- IVVD Nasdaq
- Market Cap
- NTRB 59.1M
- IVVD 69.0M
- IPO Year
- NTRB N/A
- IVVD 2021
- Fundamental
- Price
- NTRB $7.50
- IVVD $0.75
- Analyst Decision
- NTRB Buy
- IVVD Strong Buy
- Analyst Count
- NTRB 1
- IVVD 3
- Target Price
- NTRB $13.00
- IVVD $5.85
- AVG Volume (30 Days)
- NTRB 82.0K
- IVVD 1.8M
- Earning Date
- NTRB 05-30-2025
- IVVD 08-13-2025
- Dividend Yield
- NTRB N/A
- IVVD N/A
- EPS Growth
- NTRB N/A
- IVVD N/A
- EPS
- NTRB N/A
- IVVD N/A
- Revenue
- NTRB $2,398,437.00
- IVVD $36,688,000.00
- Revenue This Year
- NTRB $560.75
- IVVD $446.60
- Revenue Next Year
- NTRB $588.39
- IVVD $112.63
- P/E Ratio
- NTRB N/A
- IVVD N/A
- Revenue Growth
- NTRB 18.92
- IVVD N/A
- 52 Week Low
- NTRB $3.72
- IVVD $0.35
- 52 Week High
- NTRB $11.78
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- NTRB 59.79
- IVVD 43.27
- Support Level
- NTRB $7.00
- IVVD $0.70
- Resistance Level
- NTRB $7.90
- IVVD $1.03
- Average True Range (ATR)
- NTRB 0.66
- IVVD 0.07
- MACD
- NTRB -0.01
- IVVD -0.03
- Stochastic Oscillator
- NTRB 37.45
- IVVD 12.75
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.